Olmesartan: Difference between revisions
Jump to navigation
Jump to search
NCLEX nursing pharmacology monographs — batch import |
Add medication infobox (Drugbox) to monographs |
||
| Line 1: | Line 1: | ||
{{Drugbox | |||
| name = Olmesartan | |||
| brand = Benicar | |||
| therapeutic = Antihypertensive | |||
| pharmacologic = ARB | |||
| onset = Peak effect about 2 weeks; duration 24 hours. | |||
| halflife = Half-life about 13 hours; no routine level. | |||
| routes = PO (oral) | |||
| highalert = No | |||
| blackbox = <span style="color:#b00020;">'''Yes'''</span> (see Safety) | |||
| antidote = None specific. | |||
| pregnancy = Contraindicated. | |||
}} | |||
<div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;"> | <div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;"> | ||
''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.'' | ''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.'' | ||
Latest revision as of 16:09, 17 June 2026
| Drug monograph · NCLEX study reference | |
| Trade names | Benicar |
|---|---|
| Therapeutic class | Antihypertensive |
| Pharmacologic class | ARB |
| Onset / peak / duration | Peak effect about 2 weeks; duration 24 hours. |
| Half-life / level | Half-life about 13 hours; no routine level. |
| Routes | PO (oral) |
| High-alert (ISMP) | No |
| Black box warning | Yes (see Safety) |
| Antidote / reversal | None specific. |
| Pregnancy / lactation | Contraindicated. |
Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.
Olmesartan (brand name Benicar) — Antihypertensive; ARB.
Identification
- Therapeutic class: Antihypertensive.
- Pharmacologic class: ARB.
Pharmacology
- Mechanism of action: Same AT1 blockade.
- Onset / peak / duration: Peak effect about 2 weeks; duration 24 hours.
- Half-life / therapeutic level: Half-life about 13 hours; no routine level.
Clinical use
- Indications: Hypertension.
- Usual dose, route, frequency: 20 to 40 mg PO once daily.
- Maximum dose / adjustments: Max 40 mg/day.
Safety
- Contraindications: Pregnancy, aliskiren in diabetes.
- Black box warning: Fetal toxicity.
- Interactions: Class ARB interactions; bile acid sequestrants reduce absorption.
- Pregnancy / lactation: Contraindicated.
- High-alert: No.
Adverse effects
- Common side effects: Dizziness, headache.
- Serious effects to report: Angioedema, hyperkalemia, sprue-like enteropathy (severe chronic diarrhea with weight loss).
- Antidote / reversal: None specific.
Nursing process
- Assessment before administration: Blood pressure, potassium, renal function, pregnancy status.
- Interventions during therapy: Assess for chronic diarrhea.
- Monitor: Blood pressure, potassium, renal function, weight.
- Evaluation / expected outcome: Blood pressure at goal.
Patient teaching
- Patient teaching: Report persistent diarrhea or weight loss.
- Notify provider if: Swelling, severe or chronic diarrhea, pregnancy.
- Administration tips: With or without food.